Semaphorin 3A is a marker for disease activity and a potential immunoregulator in systemic lupus erythematosus

Zahava Vadasz(Bnai Zion Medical Center), Elias Toubi(Bnai Zion Medical Center), Gera Neufeld(Technion – Israel Institute of Technology), Tharwat Haj(Technion – Israel Institute of Technology), Ofra Kessler, Aharon Kessel(Technion – Israel Institute of Technology), Katalin Halasz(Bnai Zion Medical Center), Itzhak Rosner(Bnai Zion Medical Center), Dina Attias(Bnai Zion Medical Center), Gleb Slobodin(Bnai Zion Medical Center)
Arthritis Research & Therapy
June 14, 2012
10.1186/ar3881
Cited by 72

Related Papers

The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria
|Allergy|2018|1.4k
The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria
|Allergy|2021|1.2k
The <scp>EAACI</scp>/<scp>GA</scp><sup>2</sup><scp>LEN</scp>/<scp>EDF</scp>/<scp>WAO</scp> Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update
|Allergy|2014|1.2k
The EAACI/GA2LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update
|Dermatology Review|2015|428
Clinical and laboratory parameters in predicting chronic urticaria duration: a prospective study of 139 patients
|Allergy|2004|301